FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379285510> ?p ?o ?g. }

• W4379285510 endingPage "e12500" @default.
• W4379285510 startingPage "e12500" @default.
• W4379285510 abstract "e12500 Background: Breast cancer is a major public health problem. Despite knowing the management, clinicians are forced to provide less than optimal care when diagnostic and/or treatment are lacking. For that, we decided to do a review about breast cancer treatment during the 21 st century in Dr. Heriberto Pieter Oncology Institute. Methods: A retrospective study was done to describe and evaluate the management of patients with breast cancer. A random sample of 100.00 patients was selected, which was reduced to 64.00 after the inclusion-exclusion criteria application like lacking immunohistochemistry, partial treatment. and less than 5 years with the diagnosis. Results: Molecular subtypes included luminal A: estrogen receptor + and/or progesterone receptor + , Her2Neu 3 - (44%); luminal B: estrogen receptor + and/or progesterone receptor + , Her2Neu 3+ (9%); Her2Neu 3 : estrogen receptor-, progesterone receptor - , Her2Neu 3+ (19%); basal-like: estrogen receptor - , progesterone receptor - , Her2Neu 3- (28%). Chemotherapy history: 63% with neoadjuvant chemotherapy; 78% with adjuvant chemotherapy, 18.75% as primary and 59.37% as secondary; 17% with palliative chemotherapy, 3% as primary and 14% as secondary. Surgical history: 31% with primary modified radical mastectomy (MRM), 63% with secondary MRM, and 2% with quadrantectomy. Radiotherapy: 11% with primary radiation therapy (RT), 36% with secondary RT, and 3% with palliative RT. Hormonal therapy of patients: 33% with tamoxifen, 11% with aromatase inhibitors, 8% with combination of hormonal therapy, and 22% with extended adjuvant hormone therapy of more than 5 years. Primary endpoints were disease-free survival at 5 years (67%), objective response rate to neoadjuvant chemotherapy (100% according to RECIST criteria), and overall survival at 5 years (87.5%). Currently in Dominican Republic there is availability of more target therapy for Her2Neu 3 like pertuzumab, lapatinib, other drugs for positive hormone receptor named CDK4/6 inhibitors (palbociclib, ribociclib), olaparib for germline BRCA mutation and pembrolizumab for basal like or triple negative breast cancer (TNBC). Finally, according to the latest World Health Organization (WHO) data published in 2020, breast cancer deaths in Dominican Republic reached 1,460 or 2.14% of total deaths. The age adjusted death rate is 28.28 per 100,100 and the number of new cases in 2020 for breast cancer was 3,412 (17.2%). Conclusions: This review allows us to track the evolution of breast cancer management in Dominican Republic during the 21 st century. It highlights the efforts made to apply guidelines on breast cancer management in general and global objective response to neoadjuvant regimen. It also highlights the need to implement more primary prevention and early detection since 52% of patients belong to the locally advanced category. [Table: see text]" @default.
• W4379285510 created "2023-06-05" @default.
• W4379285510 creator A5091857498 @default.
• W4379285510 creator A5092084536 @default.
• W4379285510 creator A5092084537 @default.
• W4379285510 date "2023-06-01" @default.
• W4379285510 modified "2023-09-25" @default.
• W4379285510 title "Evolution of breast cancer management in the Dominican Republic in the 21^st century." @default.
• W4379285510 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e12500" @default.
• W4379285510 hasPublicationYear "2023" @default.
• W4379285510 type Work @default.
• W4379285510 citedByCount "0" @default.
• W4379285510 crossrefType "journal-article" @default.
• W4379285510 hasAuthorship W4379285510A5091857498 @default.
• W4379285510 hasAuthorship W4379285510A5092084536 @default.
• W4379285510 hasAuthorship W4379285510A5092084537 @default.
• W4379285510 hasConcept C121608353 @default.
• W4379285510 hasConcept C126322002 @default.
• W4379285510 hasConcept C143998085 @default.
• W4379285510 hasConcept C2776694085 @default.
• W4379285510 hasConcept C2777164284 @default.
• W4379285510 hasConcept C2777176818 @default.
• W4379285510 hasConcept C2777982462 @default.
• W4379285510 hasConcept C2778311097 @default.
• W4379285510 hasConcept C509974204 @default.
• W4379285510 hasConcept C530470458 @default.
• W4379285510 hasConcept C71924100 @default.
• W4379285510 hasConcept C84606932 @default.
• W4379285510 hasConcept C98717036 @default.
• W4379285510 hasConceptScore W4379285510C121608353 @default.
• W4379285510 hasConceptScore W4379285510C126322002 @default.
• W4379285510 hasConceptScore W4379285510C143998085 @default.
• W4379285510 hasConceptScore W4379285510C2776694085 @default.
• W4379285510 hasConceptScore W4379285510C2777164284 @default.
• W4379285510 hasConceptScore W4379285510C2777176818 @default.
• W4379285510 hasConceptScore W4379285510C2777982462 @default.
• W4379285510 hasConceptScore W4379285510C2778311097 @default.
• W4379285510 hasConceptScore W4379285510C509974204 @default.
• W4379285510 hasConceptScore W4379285510C530470458 @default.
• W4379285510 hasConceptScore W4379285510C71924100 @default.
• W4379285510 hasConceptScore W4379285510C84606932 @default.
• W4379285510 hasConceptScore W4379285510C98717036 @default.
• W4379285510 hasIssue "16_suppl" @default.
• W4379285510 hasLocation W43792855101 @default.
• W4379285510 hasOpenAccess W4379285510 @default.
• W4379285510 hasPrimaryLocation W43792855101 @default.
• W4379285510 hasRelatedWork W2000536166 @default.
• W4379285510 hasRelatedWork W2104296738 @default.
• W4379285510 hasRelatedWork W2126511903 @default.
• W4379285510 hasRelatedWork W2131308508 @default.
• W4379285510 hasRelatedWork W2172254302 @default.
• W4379285510 hasRelatedWork W2367105124 @default.
• W4379285510 hasRelatedWork W2397762222 @default.
• W4379285510 hasRelatedWork W2429402395 @default.
• W4379285510 hasRelatedWork W2942716128 @default.
• W4379285510 hasRelatedWork W2181705735 @default.
• W4379285510 hasVolume "41" @default.
• W4379285510 isParatext "false" @default.
• W4379285510 isRetracted "false" @default.
• W4379285510 workType "article" @default.